
BISINILAR WORKSHOP 2023 D2-03 FEBRUARY, 2023 | GOA



Kanak Raj, Anurag P. Srivastava, Thummala Praveen, Rajiv Bharadwaj, Sunit Maity, Vaishali Sinha and Sridevi Khambhampaty, Biopharmaceutical Development Department, Syngene International Ltd, Biocon Park, Bengaluru Karnataka – 560099, E. Mail: kanak.raj@syngeneintl.com


Introduction

Plasmid DNA is a new generation biotechnology product (gene medicines and DNA vaccines) that is just beginning to enter the marketplace. Plasmid DNA vectors may find application as preventive or therapeutic DNA vaccines for viral, bacterial, parasitic diseases or for other indications such as cancer and gene therapy products [1]. However, large scale production of pDNA is challenging, due to effect of production parameters on the extent of plasmid supercoiling, generational loss and instability [2]. Syngene scientists were able to overcome these challenges with their extensive experience and novel ideas, resulting in a pDNA production platform process with high pDNA yield and purity. Microbial Upstream team at Syngene has developed a high cell density fed-batch fermentation platform process to produce pDNA at high titers (>1 g/L), while downstream scientists have overcome the challenges by implementing a custom-made cell lysis vessel, which allowed to control critical parameters such as lysis pH, agitation, and temperature. The Process Development was supported by state-of-the-art analytical capability at Syngene.



-Cell density achieved ~140 O.D₆₀₀

AEX: Purity analysis of pDNA batch



~0.1 g/L >> 0.4 g/L >>> 1 g/L; **↑6X-9X Productivity Enhancements**

3) Process resulted in yield of 25-40% enriched with the supercoiled form of

supercoiled pDNA.

ALS

2)

provides good

plasmid DNA

Conclusion

After successful planning and experimentation, Syngene scientists were able to develop a platform process for plasmid DNA production, with high titers > 1 g/L at Upstream and >25% recovery at Downstream. The platform process has been successfully tested across 2L, 10L and 50L production scales, for both high and low copy number plasmids. Syngene pDNA platform process has served and continues to serve the needs of a diversity of Syngene clients. The authors would like to thank Syngene International Ltd., for funding this project

Acknowledgement

of

yield

References

- 1. Mark A. Eiteman and Elliot Altman, Overcoming acetate in *Escherichia coli* recombinant protein fermentations, 2006, TRENDS in Biotechnology Vol.24 No.11
- James A. Williams, Aaron E. Carnes, Clague P. Hodgson, Plasmid DNA vaccine vector design - Impact on efficacy, safety and upstream production, 2009, Biotechnology Advances, 27, 353–370